Description du projet
Réexamen de la neurodégénérescence au niveau des synapses
Les troubles neurodégénératifs tels que les maladies d’Alzheimer et de Parkinson se caractérisent par le mauvais repliage et l’agrégation de protéines spécifiques. Alors que de nombreuses recherches se sont concentrées sur la dégénérescence des neurones, de plus en plus d’éléments indiquent que ces maladies pourraient en fait commencer au niveau des synapses. Financé par le programme Actions Marie Skłodowska-Curie, le projet SYNDEGEN réunira des experts du domaine pour étudier le rôle physiologique de ces protéines et leur implication dans le dysfonctionnement synaptique. Le consortium s’attachera à fournir une formation complète à la prochaine génération de chercheurs dans ce domaine, facilitant ainsi une nouvelle compréhension et le développement de nouvelles approches thérapeutiques.
Objectif
Neurodegenerative diseases (NDDs) of aging are a growing burden on societies. Although studies on the degeneration of neurons have been a main focus of research, increasing evidence points to synapses as the site where Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD) begin. There is growing evidence that synapses are sites of early and aberrant protein misfolding, aggregation and spread in NDDs. A key problem in research on NDDs has been that the normal physiological roles at synapses of the aggregation-prone proteins (β- amyloid/amyloid precursor protein, tau, α-synuclein and huntingtin), which are linked pathologically and genetically to these diseases, are not known. Using cutting-edge technologies and multidisciplinary approaches the SYNDEGEN consortium aims to bring together leading experts in cell biology, synapse biology and imaging, stem cell biology and NDDs in Europe to determine the molecular and cellular mechanisms whereby synapses become dysfunctional in AD, PD and HD for the purpose of developing novel therapies. The goal of the consortium is to train talented young scientists in interdisciplinary, innovative and collaborative research aimed at the development of novel molecular based treatment strategies for these major diseases of aging. A gap in the training of students in these important diseases is that disease expertise and novel methods to study synapses are localized in isolated groups in different locations in the EU. Similar questions are being asked about the mechanisms of synaptic dysfunction in AD, PD and HD, but no one university or company has sufficiently broad knowledge and technical expertise required to study and develop therapies for synaptic dysfunction in these disorders. This training programme will be implemented in 6 academic centres and 2 SMEs representing a comprehensive, highly interactive and multidisciplinary partnership.
Champ scientifique
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinephysiologypathophysiology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsprotein folding
- medical and health sciencesbasic medicineneurologyparkinson
Programme(s)
Régime de financement
MSCA-ITN-ETN - European Training NetworksCoordinateur
22100 Lund
Suède